Zecotek introduces the SL 1.4 Fiber Coupled Laser
Vancouver, February 14, 2008 – Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I) today announced the introduction of its SL 1.4 Fiber Coupled Laser, designed specifically for surgical applications in the ophthalmic market where it can be used for a variety of coagulatory procedures.
“We are very pleased to be introducing this new laser,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek. “The SL 1.4 Fiber Coupled Laser has been specifically designed to meet a need in a medical market segment with large growth potential. The laser will form the major component in ophthalmic laser systems. We see this as another excellent example of Zecotek’s strength in the innovation and commercialization of leading edge photonic technologies.”
Zecotek’s SL 1.4 Laser utilizes a proprietary design and offers a more effective and less expensive solution than presently used holmium lasers. The 1.4 micron wavelength can be used for a variety of coagulatory surgical procedures including Laser Thermal Keratoplasty (LTK), a refractive surgical procedure which uses an infrared laser to reshape the cornea for correction of low ranges of hyperopia (farsightedness), presbyopia (age-related loss of focus) and over-corrections from radial keratotomy and LASIK procedures. The company is currently preparing for filing for patent protection in a number of jurisdictions.
LTK treatment is differentiated from LASIK and similar procedures in that it reshapes the cornea but does not cause permanent tissue loss. The Excimer laser used in LASIK treatments emits in the deep Ultra-violet wavelengths and uses a cool beam to vaporize corneal tissue. The 1.4 micron laser line matches the absorption spectrum of water in the cornea and is considered a safer and more compatible wavelength. The treatment has the advantage of not being fully permanent, but can be sustained with periodic treatment. Other benefits include no scarring in the central cornea, a low risk of dry eyes and immediate vision improvement.
Zecotek’s SL 1.4 Fiber Coupled Laser is undergoing initial trials in Russia, where LTK is a recognized treatment. The LTK procedure is currently under investigation by the FDA for approval in the United States. The SL 1.4 laser was developed by Zecotek Laser Systems Pte Ltd. and will be supplied to bio-medical OEMs and institutions for testing and design-in purposes.
Zecotek also announces that discussions continue with Fujikura Inc. with respect to the previously announced agreement-in-principle. Both parties are working to finalize structural and operational details of the proposed agreement where Fujikura will contribute, technical support and manufacturing know-how for Zecotek laser products to be manufactured and distributed by Fujikura.
Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing leading-edge products: crystals, photo detectors, lasers, imaging and 3D display technologies, for medical, biotech, industrial, nanotech and atomic/molecular science applications. Founded in 2003, the company has three distinct operating divisions: imaging, lasers and 3D display and labs located in Canada, the United States, Singapore, Malaysia and Russia. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit Zecotek Photonics.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For product and technical information please contact:
Zecotek Photonics Inc., SUSANA MENDEZ ALCALA, SMA@zecotek.com, T: (604) 827-5232
For corporate information please contact:
Zecotek Photonics Inc., MICHAEL MINDER, CFO; VP Corporate Development, T: (604) 827-5203
For investor information please contact:
Caliber Capital & Communications, TIM MCNULTY, T: (778) 327-6678, E: email@example.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.